Translational molecular research has established a novel clinical approach in endometrial cancer patients

Abstract

Endometrial cancer (EC) is the most common gynecological tumor in developed countries. Nowadays, molecular biomarkers have become increasingly important in the management of EC patients, helping in early detection, risk stratification, prognosis and response to the treatment, and qualification for novel immunotherapies, especially in EC patients with metastatic disease or recurrence. When EC tumor molecular profiling is combined with the standard histopathological features such as clinical stage, histologic grading and evaluation of lymphovascular space invasion, the final therapeutic outcome may bring benefits in terms of personalized and efficient management.

Keywords: endometrial cancer; molecular markers; translational researches.